ArticleClinical and translational medicine2022
Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort.
Abstract readLetter
In one paragraph
Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Trial
- Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.Therapeutic advances in respiratory diseaseTrial
- Clinical diagnosis and treatment of eosinophilic asthma by respiratory physicians in China: a cross-sectional survey.Journal of thoracic disease · 2026Article
- Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.ERJ open research · 2026Article
- Article
- Characteristics and asthma control status in the Korean Severe Asthma Registry-2: a real-world analysis.ERJ open research · 2026Article
- NLRP3-mediated epithelial pyroptosis involved in airway hyperresponsiveness in combined eosinophilic and neutrophilic asthma.Cell communication and signaling : CCS · 2026Article
- Desmoglein-2 dysregulation impairs epithelial barrier integrity in eosinophilic asthma.Respiratory research · 2026Article
- Itaconate Modulates Neutrophil Homeostasis to Ameliorate Airway Inflammation in Diesel Exhaust Particles-exacerbated Asthma via Inhibiting NETs Formation.International journal of biological sciences · 2026Article
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.Frontiers in allergy · 2026Review
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Quantitative Computed Tomographic Clusters in C-BIOPRED Asthma Cohort: Association with Sputum Proteomics.MedComm · 2025Article
- SIRT5 Alleviated Eosinophilic Asthma Through ROS Inhibition and Nrf2/HO-1 Activation.Inflammation · 2025Article
- Transforming Care in China by Using Public-Private Partnerships to Unlock the Power of Patient-Centered Real-World Data.Pharmaceutical medicine · 2025Review
- Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: AAllergy, asthma & immunology research · 2025Article
- C-BIOPRED severe asthma clinical phenotypes: link to complement and coagulation pathways and galectin 10.ERJ open research · 2025Article
- Predictive effects of advanced lung cancer inflammation index and serum vitamin D on mortality in patients with asthma.Nutrition journal · 2025Article
- Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.ERJ open research · 2024Article
- Clinical characteristics of obese, fixed airway obstruction, exacerbation-prone phenotype and comorbidities among severe asthma patients: a single-center study.BMC pulmonary medicine · 2024Article
- Lonicerin attenuates house dust mite-induced eosinophilic asthma through targeting Src/EGFR signaling.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Qingling ZhangDepartment of pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-2433-2849
Xiuhua FuDepartment of Respiratory Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China.
Changzheng WangDepartment of Respiratory Medicine, Xinqiao Hospital, Army Military Medical University, Chongqing, China.
Huahao ShenDepartment of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Lei ZhuDepartment of Respiratory Medicine, Zhongshan Hospital, Shanghai, China.
Guochao ShiDepartment of Respiratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID 0000-0003-1987-8334
Zhongmin QiuDepartment of Respiratory Medicine, Shanghai Tongji Hospital, Shanghai, China.
Zhongguang WenDepartment of Respiratory Medicine, The First Affiliated Hospital of PLA General Hospital, Beijing, China.
Wei GuDepartment of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Wei LuoDepartment of pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lina ZhaoAstraZeneca, Shanghai, China.
Yunqin ChenAstraZeneca, Shanghai, China.
Sam LimAstraZeneca, Shanghai, China.
Chang XiaoAstraZeneca, Shanghai, China.
Jian KangDepartment of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, China.
Yunhui ZhangDepartment of Respiratory Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Mao HuangDepartment of Respiratory Medicine, Jiangsu Province Hospital, Nanjing, China.
Jinfu XuDepartment of Respiratory Medicine, Shanghai Pulmonary Hospital, Shanghai, China.
Kewu HuangDepartment of Respiratory Medicine, Beijing Chao-Yang Hospital, Beijing, China.
Qiang LiDepartment of Respiratory Medicine, Shanghai General Hospital, Shanghai, China.
Xiangyan ZhangDepartment of Respiratory Medicine, Guizhou Province People's Hospital, Guiyang, China.
Jianping ZhaoDepartment of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoxia LiuDepartment of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shenghua SunDepartment of Respiratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Huaping TangDepartment of Respiratory Medicine, Qingdao Municipal Hospital, Qingdao, China.
Bei HeDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing, China.
Shaoxi CaiDepartment of Respiratory Medicine, Nanfang Hospital of Southern Medical University, Guangzhou, China.
Ping ChenDepartment of Respiratory Medicine, The General Hospital of Shenyang Military, Shenyang, China.
Chunhua WeiDepartment of Respiratory Medicine, Weifang Asthma hospital, Weifang, China.
Guangfa WangDepartment of Respiratory Medicine, Peking University First Hospital, Beijing, China.
Ping ChenDepartment of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Lixin XieCollege of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, China.
Jiangtao LinDepartment of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Yuling TangDepartment of Respiratory Medicine, The First Hospital of Changsha, Changsha, China.
Zhihai HanDepartment of Respiratory Medicine, Navy General Hospital, Beijing, China.
Kian Fan ChungNational Heart and Lung Institute, Imperial College London, & Royal Brompton & Harefield NHS Foundation Trust, London, SW3, UK.ORCID 0000-0001-7101-1426
Nanshan ZhongDepartment of pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
C-BIOPRED consortiumDepartment of pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Funding
Astra-Zeneca, ChinaMedical Research Council MR/T010371/1
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAsthmaChinaCohort StudiesFemaleHumansMaleMiddle AgedPulmonary EosinophiliaSurveys and Questionnairesblood eosinophil countcigarette smokingexacerbationsfractional exhaled nitric oxidesevere asthma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.